Syndax Pharmaceuticals
SNDX
74 hedge funds and large institutions have $68.9M invested in Syndax Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 16 closing their positions.
607% more call options, than puts
Call options by funds: $2.05M | Put options by funds: $290K
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 75 → 74 (-1)
3.38% less ownership
Funds ownership: 65.66% → 62.28% (-3.4%)
44% less capital invested
Capital invested by funds: $124M → $68.9M (-$55.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$4.51M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$4.13M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$970K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$934K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$614K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.06M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.82M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.37M |
| 4 |
O
OrbiMed
New York
|
-$1.23M |
| 5 |
BlackRock
New York
|
-$1M |
SNDX Hedge Fund Activity: Q4 2018 in Review
74 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2018, worth a combined $68.9M — down 44% from $124M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SNDX and 15 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 25 added.
The largest buyer was 683 Capital Management, adding an estimated $4.51M. The largest seller was Millennium Management, cutting an estimated $3.06M.
- 74 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2018, down from 75 in Q3 2018.
- Funds reported $68.9M of Syndax Pharmaceuticals stock for Q4 2018, down 44% quarter-over-quarter.
- 15 funds opened new Syndax Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of -1 holder.
- The largest Syndax Pharmaceuticals buyer in Q4 2018 was 683 Capital Management, an estimated $4.51M added.
- The largest Syndax Pharmaceuticals seller in Q4 2018 was Millennium Management, an estimated $3.06M sold.
Based on aggregated 13F filings for Q4 2018.